Antiphospholipid syndrome (APS) is an immune-mediated acquired disorder characterized
by venous, arterial or small vessels thromboses and/or obstetrical morbidity, and
the persistent presence of antiphospholipid antibodies (APL). APS is also associated
with other “non-criteria” manifestations [
[1]
], of which thrombocytopenia is the most frequent, present in up to 29% of SLE-associated
APS patients [
[2]
].Thrombocytopenia is thought to be due to peripheral platelet consumption and/or destruction
subsequently to their activation by APL. In addition, platelets may play a central
role in APS, as they have been shown to be the main target of anti- β2GPI / β2GPI complexes [
[3]
], and their therapeutic inhibition seems to be effective in preventing thrombosis
[
[4]
].- Arnaud L
- Mathian A
- Devilliers H
- Ruffatti A
- Tektonidou M
- Forastiero R
- Pengo V
- Lambert M
- Lefevre G
- Martinez-Zamora MA
- Balasch J
- Wahl D
- Amoura Z
Patient-level analysis of five international cohorts further confirms the efficacy
of aspirin for the primary prevention of thrombosis in patients with antiphospholipid
antibodies.
Autoimmun Rev. 2015; 14: 192-200
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Non-criteria manifestations of antiphospholipid syndrome.Lupus. 2010; 19: 424-427
- Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Autoimmun Rev. 2019; 102395
- Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.Blood. 2014; 124: 611-622
- Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies.Autoimmun Rev. 2015; 14: 192-200
- Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.J Thromb Haemost JTH. 2017; 15: 1782-1787
- Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE treatment and research group registry IV.Int J Rheum Dis. 2015; 18: 654-660
- Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.Lupus. 2017; 26: 163-169
- Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile.Lupus. 2017; 26: 983-988
- The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndrome.Rheumatol Int. 2014; 34: 1599-1605
- Thrombocytopenia in high-risk patients with antiphospholipid syndrome.J Thromb Haemost JTH. 2018; 16: 529-532
Article info
Publication history
Published online: October 17, 2020
Accepted:
October 14,
2020
Received in revised form:
September 30,
2020
Received:
September 7,
2020
Identification
Copyright
© 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
